Inclusion Criteria:

- Men and Women of all ethnic groups whose age is ≥ 18 years old.

- Diagnosis of AML or CML blast crisis, according to World Health Organization (WHO)
criteria, except acute promyelocytic leukemia AML-M3 French-American-British (FAB)
subgroup. A documentation of relapse is required by a bone marrow/aspirate within 4
weeks of registration.

- Refractory or Relapsed AML. Refractory AML is defined as failure to achieve CR after
2 cycles of induction chemotherapy or persistent (>40%) bone marrow blasts after one
cycle of chemotherapy induction.

- Relapsed AML is defined as any evidence of disease recurrence after achieving
complete response (CR) (more than 5% myeloblasts). Early relapse is defined as that
occurring within 12 months and late relapse is defines as that occurring after 12
months.

- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

- Patients must sign a written informed consent.

- Females of childbearing potential (FOCP) must not be pregnant or actively nursing a
child. They must have a negative pregnancy test 7 days before initiation of study
drug administration

- Postmenopausal women must be amenorrheic for at least 12 months to be considered of
non-childbearing potential.

- Male and females of reproductive potential must agree to employ an effective barrier
method of birth control throughout the duration of the trial and for 3 months
following study medication discontinuation.

- Prior allogeneic or autologous stem cell transplantation is allowed.

Exclusion Criteria:

- Abnormal Kidney Functions: creatinine ≥2.5mg/dL.

- Abnormal Liver Functions: Bilirubin more 3 mg/dL, transaminases (AST/ALT) more that
2.5 times the institutional upper limits of normal (IULN).

- Systemic active infection, unless controlled on active therapy.

- Patients with Grade III/IV cardiac problems as defined by the New York Heart
Association (NYHA) Criteria ( i.e., congestive heart failure, myocardial infarction
within 6 months of the study), or ejection fraction (EF)< 30%.

- Patient has known chronic liver disease (i.e., chronic active hepatitis, hepatitis B,
hepatitis C, and cirrhosis).

- Patient has known diagnosis of human immunodeficiency virus (HIV) infection.

- History of other malignancy, except non-melanotic skin cancers or no disease
recurrence/progression for more than 2 years.

- Patients that have received investigational agents within 1 month of study entry.

- History of allergic reaction attributed to compounds of similar chemical or biologic
composition to Gleevec or any component of the CLAG regimen

- Prior therapy with CLAG chemotherapy regimen

- Any adverse event attributable to previous chemotherapy regimen must be resolved to
grade 1 or less at time of registration.